Harmony Biosciences
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 160m | 305m | 438m | 582m | 710m | 843m | 997m |
% growth | 2565 % | 91 % | 43 % | 33 % | 22 % | 19 % | 18 % |
EBITDA | 13.9m | 87.5m | 120m | 231m | 185m | 310m | 394m |
% EBITDA margin | 9 % | 29 % | 27 % | 40 % | 26 % | 37 % | 40 % |
Profit | (36.9m) | 34.6m | 181m | 129m | 137m | 229m | 305m |
% profit margin | (23 %) | 11 % | 41 % | 22 % | 19 % | 27 % | 31 % |
EV / revenue | 12.7x | 8.0x | 7.3x | 3.0x | 2.5x | 2.0x | 1.3x |
EV / EBITDA | 145.3x | 28.0x | 26.7x | 7.6x | 9.5x | 5.3x | 3.3x |
R&D budget | 19.4m | 30.4m | 70.9m | 76.1m | - | - | - |
R&D % of revenue | 12 % | 10 % | 16 % | 13 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $270m | Growth Equity VC | |
$200m | Debt | ||
$50.0m | Series C | ||
$200m | Debt | ||
N/A | $128m Valuation: $1.5b 250.2x EV/LTM Revenues -10.5x EV/LTM EBITDA | IPO | |
$300m | Post IPO Debt | ||
$30.0m | Post IPO Equity | ||
* | $185m | Post IPO Debt | |
* | N/A | Post IPO Equity | |
Total Funding | $320m |
Recent News about Harmony Biosciences
EditHarmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company operates in the healthcare sector, specifically targeting conditions that have limited treatment options. Harmony Biosciences serves patients, healthcare providers, and the broader medical community by bringing breakthrough science within reach. The business model revolves around the research, development, and commercialization of novel medications, generating revenue through the sale of these specialized therapies. The company invests heavily in scientific research to identify new clinical possibilities and advance the treatment landscape for rare neurological disorders.
Keywords: biopharmaceutical, rare diseases, neurological, innovative therapies, commercialization, healthcare, research, development, novel medications, breakthrough science.